SeattleGenetics Initiates Phase II Clinical Trial Of Brentuximab Vedotin

SeattleGenetics has initiated a phase II clinical trial of brentuximab vedotin (SGN-35), an antibody-drug conjugate (ADC), for the re-treatment of patients with Hodgkin lymphoma and systemic anaplastic large cell lymphoma (ALCL).

Reportedly, the phase II multi-center trial will assess safety and antitumor response to re-treatment with brentuximab vedotin.

The trial is designed to enroll up to 50 patients with relapsed or refractory Hodgkin lymphoma or systemic ALCL, who have previously achieved a complete or partial response to therapy with brentuximab vedotin. Patients will receive 1.8 milligrams per kilogram of brentuximab vedotin every three weeks.

Thomas Reynolds, CMO of Seattle Genetics, said: “Data from our phase I clinical trials suggest that patients who responded to brentuximab vedotin, but who relapse after discontinuing their original treatment regimen, may benefit from receiving additional brentuximab vedotin therapy.”

“By evaluating brentuximab vedotin in this setting, there is potential to provide further patient benefit and offer an additional therapeutic option for managing relapsed Hodgkin lymphoma and systemic ALCL,” he added.